Clinical Trial

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Name: [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) — clinical trial record (NCT07020806)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-06-05; most recent amendment 2026-03-19.

Trial Details

NCT Number	NCT07020806
Lead Sponsor	University of California, Davis Collaborators: Dr. Helen K Chew, University of California Davis, Dr. Cameron Foster, University of California Davis, Society of Nuclear Medicine and Molecular Imaging
Conditions	Metastatic Lobular Breast Carcinoma
Enrollment	30 participants
Start Date	2025-11-18
Primary Completion	2027-06 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-23